Showing 5621-5630 of 5956 results for "".
- New Laser Helps Doctors Image Full Eye in 3Dhttps://modernod.com/news/new-laser-helps-doctors-image-full-eye-in-3d/2476348/Scientists have developed a laser-based technique that can produce a full 3D image of all the layers of the retina, allowing doctors to better diagnose and treat eye diseases such as cataracts, diabetic retinopathy, and cancer, according to an Octlight news release. Researchers from the Te
- Apellis Resumes Dosing in Its Phase 3 Program for Patients with Geographic Atrophyhttps://modernod.com/news/apellis-resumes-dosing-in-its-phase-3-program-for-patients-with-geographic-atrophy/2479589/Apellis Pharmaceuticals announced that it has resumed enrollment in its two phase 3 GA trials (DERBY & OAKS) with intravitreal APL-2 for the treatment of geographic atrophy (GA). In October 2018, Apellis
- Penetrating Keratoplasty Effective for Corneal Complications of Shingleshttps://modernod.com/news/penetrating-keratoplasty-effective-for-corneal-complications-of-shingles/2479592/Even in eyes with preoperative risks, penetrating keratoplasty (PKP) can achieve favorable results for the corneal complications of herpes zoster ophthalmicus (HZO), researchers say, as reported by Reuters. “What we learned is
- Staar Surgical Announces Strategic Cooperation Agreement with Vista Oftalmólogoshttps://modernod.com/news/staar-surgical-announces-strategic-cooperation-agreement-with-vista-oftalmologos/2479594/Staar Surgical Company announced a strategic cooperation agreement with Vista Oftalmólogos, a 49-clinic ophthalmology group spanning Spain, France, Portugal, and Morocco with more than 200 eye doctors and 1,000 employees. The agreement positions the EVO Visian ICL family of lenses as a premium an
- Aldeyra Therapeutics Provides Update on Ophthalmic Programshttps://modernod.com/news/aldeyra-therapeutics-provides-update-on-ophthalmic-programs/2476256/Aldeyra Therapeutics updated progress on ophthalmic programs at a 2019 Research & Development Day in New York City. Presentations were given by members of the Aldeyra executive team along with Dean Eliott, MD, the Stelios Evangel
- Rayner Launches New Eye Drop Formulations for Dry Eyehttps://modernod.com/news/rayner-launches-new-eye-drop-formulations-for-dry-eye/2476264/Rayner has introduced the AEON family of pre- and post-surgery eye drops to help patients with dry eye manage their condition and improve their visual outcomes. An instability in the tear film, caused by dry eye, has been shown to impact the preoperative biometry that can lead to incorrec
- Nidek Launches Upgraded AngioScan OCT-Angiography Softwarehttps://modernod.com/news/nidek-launches-upgraded-angioscan-oct-angiography-software/2476265/Nidek has announced the launch of new AngioScan upgraded OCT-Angiography software that enables visualization of retinal and choroidal microvasculature and blood flow using the RS-3000 Advance 2 OCT device. The
- FDA Approves Bausch + Lomb’s Lotemax SM For The Treatment Of Postoperative Inflammation And Painhttps://modernod.com/news/fda-approves-bausch-lombs-lotemax-sm-for-the-treatment-of-postoperative-inflammation-and-pain/2476267/Bausch + Lomb announced that the FDA has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. Compared to Lotemax Gel 0.5%, Lotemax SM delivers a submicron particle size for faste
- EyeBrain Medical and IDOC Announce Partnership to Bring Neurolens to IDOC Independent Optometristshttps://modernod.com/news/eyebrain-medical-and-idoc-announce-partnership-to-bring-neurolens-to-idoc-independent-optometrists/2476270/IDOC and eyeBrain Medical announced a multiyear partnership to bring neurolens prescription lenses to all IDOC members across the United States. Neurolenses are the first and only prescription lenses that add a contoured prism to bring the eyes into alignment. Contoured prisms have been shown in
- Ocular Therapeutix Announces Dosing of First Patient in Phase 1 Clinical Trial for the Treatment of Wet AMDhttps://modernod.com/news/ocular-therapeutix-announces-dosing-of-first-patient-in-phase-1-clinical-trial-for-the-treatment-of-wet-amd/2476273/Ocular Therapeutix announced the dosing of the first patient in a phase 1 trial of OTX-TKI (tyrosine kinase inhibitor implant) in patients with wet age-related macular degeneration (AMD). The first patient was dosed at the Sydney Retina Clinic in Sydney, Australia. “We are excited to annou